IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Reports Financial Results for Fiscal Year Ended March 31, 2017

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced its financial results for the fiscal year ended March 31, 2017. “In fiscal 2017, our major accomplishments include the advancement of our phytocannabinoid patent filing portfolio to large market indications,” Ram Mukunda, CEO of IGC, noted in the news release. “And in order to keep this focus on the medical cannabis industry, we disposed of our low-margin iron ore and electronic trading businesses, and retired about 10% of our outstanding common stock; thus reducing revenue, PP&E, and stockholder’s equity. We firmly believe that this planned strategic move positions our Company for growth in one of the fastest growing industries in America.” Though revenues were down for the period due to the company’s transition away from its electronic trading business, IGC achieved a 30.6 percent year-over-year improvement to its selling, general and administrative expenses total.

To view the full press release, visit http://nnw.fm/fc2F6

About IGC

India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland. For more information visit www.igcinc.us